趋势研判！2026年中国生发药品行业产业链、产品数量、销售额、竞争格局及发展趋势：米诺地需求旺盛，前景广阔，市场高度集中，形成明显的双巨头格局[图]

Core Insights - The hair growth medication market in China is substantial, with significant sales growth projected for key products like Minoxidil and Finasteride [1][8]. Group 1: Market Overview - In 2024, sales of Minoxidil in physical pharmacies in China are expected to exceed 400 million yuan, representing a growth of 0.8% compared to 2023 [1]. - Sales of Finasteride tablets are projected to reach 150 million yuan, showing a growth of 10.5% from 2023 [1]. - The demand for Minoxidil, recognized globally as a safe and effective topical hair growth medication, remains strong, indicating a promising market outlook [1]. Group 2: Regulatory Approvals and Product Range - As of December 29, 2025, the National Medical Products Administration (NMPA) has approved 73 domestic Finasteride products, over 96 Minoxidil products, 18 hair growth tablets, and nearly 55 other hair growth products [1][8]. - The majority of approved Finasteride products are tablets, with 47 products, and 16 raw materials, while other forms include capsules and dispersible tablets [1][8]. Group 3: Industry Structure and Competition - The hair growth medication industry in China is characterized by intense competition, with 13 companies having received NMPA approval for Minoxidil products [10]. - The Minoxidil market is highly concentrated, with Zhejiang Saime Pharmaceutical and Shandong Jingwei Pharmaceutical holding a significant market share [11]. - The Finasteride market exhibits a "dispersed competition" structure, with no clear market leader, and the tablet form being the primary battleground for competition [11]. Group 4: Industry Trends - The treatment of hair loss represents a vast and largely unmet market opportunity, with the hair growth medication industry in China continuing to expand [12].